FDA Panel Won't Back Sanofi Blood Thinner For Cancer Patients

Law360, Washington (June 20, 2012, 1:54 PM EDT) -- A U.S. Food and Drug Administration advisory panel voted overwhelmingly Wednesday not to recommend approval of a Sanofi Aventis US LLC anticoagulant for cancer patients receiving chemotherapy, saying the company's main study didn't show the drug would significantly lower patients' blood clot risks.

In a 14-1 vote with one abstention, members of the FDA Oncologic Drugs Advisory Committee voiced concerns that if the agency approved blood thinning drug semuloparin, it could spark a change in cancer treatment practices since no other drug is specifically approved to...
To view the full article, register now.